DermTech, Inc.DMTKW

時価総額

$325.5万

PER

メラノーマ診断向け分子診断サービスの有力企業。99%超の陰性予測値を誇る非侵襲パッチ式ゲノム検査とSmart Stickerを展開。2019年8月の事業結合完了や2023年1月の約30名の人員削減実施。米国中心の事業展開、欧州展開への注力。

概要財務

サマリーテーブルに戻る

	2018年 3月31日	2019年 3月31日	2019年 12月31日	2020年 12月31日	2021年 12月31日	2022年 12月31日	2023年 12月31日
Net loss	-	-	-20	-35	-78	-117	-101
Depreciation	-	-	0	0	1	2	2
Fair Value Adjustment of Warrants	-	-	-	-	1	-0	-0
Amortization of operating lease right-of-use assets	-	-	-	-	1	3	4
Stock-based compensation	-	-	1	5	13	19	19
(Accretion) Amortization of (discount) premium on marketable securities	-	-	-	-	-1	-0	1
Loss on disposal of equipment	-	-	-	-0	-0	-0	-0
Accounts receivable	-	-	0	1	2	0	-2
Inventory	-	-	-0	0	0	1	-1
Prepaid expenses and other current assets	-	-	1	0	2	1	-2
Operating lease right-of-use assets and liabilities, net	-	-	-	-	-	-3	-1
Accounts payable, accrued liabilities and deferred revenue	26,355	1	-	-	-	-	-2
Accrued compensation	-	-	-	-	-	-	-1
Net cash used in operating activities	-373,391	-444,455	-18	-29	-62	-95	-77
Purchases of marketable securities	145	-	-	42	48	31	34
Maturities and sales of marketable securities	-	-	-	2	37	-	65
Purchases of property and equipment, net	-	-	0	2	3	3	1
Net cash provided by/(used in) investing activities	-145,187,500	137	-0	-41	-13	-4	30
Proceeds from Issuance of Common Stock	-	-	20	-	-	-	5
Proceeds from Warrant Exercises	-	-	0	1	70	0	-
Proceeds from Stock Options Exercised	-	-	1	0	1	0	0
Proceeds from Stock Plans	-	-	-	-	1	1	1
Principal repayments of finance lease obligations	-	-	-	0	0	0	0
Net cash provided by financing activities	146	-136,889,634	29	79	230	1	6
Net decrease in cash, cash equivalents and restricted cash	-	-	11	9	156	-99	-41
Cash paid for interest on finance lease obligations	-	-	-	0	0	0	0
Capital Expenditures Incurred but Not yet Paid	-	-	1	0	0	0	-
Right-of-use assets obtained in exchange for lease obligations	-	-	-	-	9	51	-
Property and equipment acquired under finance leases	-	-	-	0	0	0	-
Change In Unrealized Gain Loss On Available For Sale Marketable Securities	-	-	-	-	-0	-1	1